At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an interim staff report on pharmacy benefit managers (PBM). Sens.

The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...

The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked ...

A report from the Federal Trade Commission (FTC) has determined that pharmacy benefit managers (PBMs) are linked to significant cost increases for cancer, HIV, and other critical specialty drugs.

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs.